Total Payments
$148,961
2024 Payments
$2,155
Companies
40
Transactions
1,175
Medicare Patients
10,388
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$108,435 (72.8%)
Food & Beverage$25,549 (17.2%)
Travel$8,410 (5.6%)
Consulting$6,344 (4.3%)
Education$222.97 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $108,435 | 58 | 72.8% |
| Food and Beverage | $25,549 | 1,056 | 17.2% |
| Travel and Lodging | $8,410 | 54 | 5.6% |
| Consulting Fee | $6,344 | 2 | 4.3% |
| Education | $222.97 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $73,453 | 284 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $23,937 | 125 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $19,330 | 160 | $0 (2019) |
| Mylan Specialty L.P. | $17,795 | 76 | $0 (2024) |
| Genentech USA, Inc. | $4,123 | 65 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,331 | 137 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,420 | 66 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $768.43 | 37 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $519.61 | 20 | $0 (2024) |
| Advanced Respiratory, Inc | $444.79 | 21 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,155 | 87 | GlaxoSmithKline, LLC. ($566.89) |
| 2023 | $1,676 | 77 | GlaxoSmithKline, LLC. ($522.92) |
| 2022 | $2,060 | 88 | GlaxoSmithKline, LLC. ($471.62) |
| 2021 | $3,783 | 122 | GlaxoSmithKline, LLC. ($1,722) |
| 2020 | $34,207 | 134 | GlaxoSmithKline, LLC. ($22,459) |
| 2019 | $57,279 | 261 | GlaxoSmithKline, LLC. ($37,830) |
| 2018 | $28,547 | 222 | GlaxoSmithKline, LLC. ($9,345) |
| 2017 | $19,254 | 184 | AstraZeneca Pharmaceuticals LP ($10,700) |
All Payment Transactions
1,175 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $31.51 | General |
| Category: HFCWO | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Respiratory | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Respiratory | ||||||
| 11/25/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $30.61 | General |
| Category: Cardiology | ||||||
| 11/24/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $29.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $10.56 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $31.57 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.54 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/28/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $31.58 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $26.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $29.49 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: RESPIRATORY | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 10/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: RESPIRATORY | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Respiratory | ||||||
| 09/30/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 09/30/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: VACCINES | ||||||
| 09/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: Cardio-pulmonary | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,051 | 2,776 | $972,750 | $259,252 |
| 2022 | 14 | 2,050 | 2,870 | $980,595 | $262,987 |
| 2021 | 15 | 2,554 | 3,637 | $1.1M | $314,745 |
| 2020 | 19 | 3,733 | 8,533 | $584,486 | $416,639 |
Total Patients
10,388
Total Services
17,816
Medicare Billing
$1.3M
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 224 | 391 | $172,822 | $44,929 | 26.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 122 | 218 | $160,230 | $43,664 | 27.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 297 | 469 | $126,630 | $33,962 | 26.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 192 | 297 | $120,582 | $32,836 | 27.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 158 | 167 | $98,697 | $27,044 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 244 | 346 | $108,298 | $26,650 | 24.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 130 | 136 | $60,792 | $16,193 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $28,371 | $7,210 | 25.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 240 | 275 | $26,400 | $7,056 | 26.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 97 | 105 | $21,315 | $5,558 | 26.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 97 | 105 | $20,370 | $5,528 | 27.1% |
| 71045 | X-ray of chest, 1 view | Office | 2023 | 102 | 118 | $11,092 | $2,870 | 25.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 27 | 27 | $5,400 | $2,036 | 37.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $5,967 | $1,634 | 27.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 32 | 32 | $2,720 | $1,151 | 42.3% |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | Facility | 2023 | 15 | 16 | $1,408 | $480.64 | 34.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 12 | 12 | $1,656 | $450.72 | 27.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 138 | 301 | $229,362 | $63,029 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 183 | 317 | $141,382 | $37,283 | 26.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 242 | 252 | $118,188 | $32,342 | 27.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 202 | 329 | $115,479 | $31,561 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 251 | 388 | $124,160 | $31,103 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 246 | 395 | $96,775 | $26,275 | 27.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 139 | 159 | $33,685 | $8,914 | 26.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 139 | 159 | $31,482 | $8,512 | 27.0% |
About Dr. Alan Schecter, M.D
Dr. Alan Schecter, M.D is a Pulmonary Disease healthcare provider based in Great Neck, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407895774.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Schecter, M.D has received a total of $148,961 in payments from pharmaceutical and medical device companies, with $2,155 received in 2024. These payments were reported across 1,175 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($108,435).
As a Medicare-enrolled provider, Schecter has provided services to 10,388 Medicare beneficiaries, totaling 17,816 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Great Neck, NY
- Active Since 06/05/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1407895774
Products in Payments
- NUCALA (Biological) $31,911
- TRELEGY ELLIPTA (Drug) $27,408
- BEVESPI AEROSPHERE (Drug) $15,030
- LONHALA MAGNAIR (Drug) $12,811
- Yupelri (Drug) $11,810
- ANORO (Drug) $9,266
- UTIBRON (Drug) $6,099
- BREZTRI AEROSPHERE (Drug) $5,568
- ANORO ELLIPTA (Drug) $4,525
- Xolair (Biological) $3,611
- SYMBICORT (Drug) $1,840
- OFEV (Drug) $1,441
- DUPIXENT (Biological) $707.02
- OPSUMIT (Drug) $683.14
- STIOLTO RESPIMAT (Drug) $670.06
- STIOLTO (Drug) $501.06
- XOLAIR (Biological) $444.86
- UPTRAVI (Drug) $367.23
- The VisiVest Airway Clearance System (Device) $354.35
- XARELTO (Drug) $345.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Great Neck
Dr. Jeffrey Wolf, M.d, M.D
Pulmonary Disease — Payments: $882,813
Pulmonary Disease $882,813
Dr. Robert Schreiber, M.d, M.D
Pulmonary Disease — Payments: $156,219
Pulmonary Disease $156,219
Dr. Gary Freeberg, M.d, M.D
Pulmonary Disease — Payments: $25,542
Pulmonary Disease $25,542
Dr. Michael Como, M.d, M.D
Pulmonary Disease — Payments: $20,827
Pulmonary Disease $20,827
Dr. Jonathan Waxner, M.d, M.D
Pulmonary Disease — Payments: $20,436
Pulmonary Disease $20,436
Dr. Evan Sorett, M.d, M.D
Pulmonary Disease — Payments: $19,624
Pulmonary Disease $19,624